EFFICACY AND SAFETY OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTIONS

Reducing cardiovascular risk by decreasing cardiovascular morbidity and mortality is considered one of the main objectives of modern cardiology practice. Oral anticoagulants are the basis for preventing cardioembolic stroke in patients with atrial fibrillation, a condition that often coexists with coronary heart disease. According to statistics, approximately a quarter of patients with atrial fibrillation undergo percutaneous coronary intervention at some point in their lives due to stable angina or acute coronary syndrome. This scenario presents significant challenges related to the use of multicomponent antithrombotic therapy. Antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) requires a delicate balance between preventing thromboembolic events and minimizing bleeding complications. This study evaluates the efficacy and safety of antithrombotic strategies, including dual antithrombotic therapy (DAT) and triple antithrombotic therapy (TAT), in this high-risk population. This article reviews the key clinical data and recommendations for the optimal use of combined antithrombotic therapy in patients following percutaneous coronary intervention.